Keywords
Insulin resistance
Alzheimer's Disease
Type 2 Diabetes Mellitus
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Describe the correlation between insulin resistance and the development of Alzheimer’s disease. Literature review: Alzheimer’s disease is the most common form of neurodegenerative dementia, characterized by the loss of nerve cells and synaptic destruction, especially in brain areas associated with cognitive function, such as the cerebral cortex and hippocampus. The pathology involves the accumulation of beta-amyloid plaques and neurofibrillary tangles formed by tau protein, compromising neurological performance and blocking electrical signals. Patients with type 2 diabetes mellitus exhibit systemic insulin resistance, which may contribute to the development of the disease in question, as brain insulin resistance reduces glucose uptake by neurons, impairing neuroplasticity and cognition. Research is exploring new therapies, such as immunotherapies, to prevent neuroinflammation and protein accumulation. Conclusions: Insulin resistance in the brain impairs glucose uptake by neurons, contributing to the development and progression of Alzheimer’s disease. Future research should focus on therapeutic strategies that modulate this resistance to improve prevention and treatment of the disease.
References
ANDRADE LJDEO, et al. Brain insulin resistance and Alzheimer’s disease: a systematic review. Dementia & neuropsychologia, 2024; 18: e20230032.
ARNOLD SE, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nature reviews. Neurology, 2018; 14(3): 168–181.
ARVANITAKIS Z, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Archives of Neurology, 2004; 61: 661-666.
BARBARA XS, et al. Principais fatores de risco modificáveis para a demência de Alzheimer. Revista Eletrônica Acervo Saúde, 2024; 24(1): e14785.
BURILLO J, et al. Insulin resistance and diabetes mellitus in Alzheimer’s disease. Cells (Basel, Switzerland), 2021; 10(5): 1236.
CAETANO LAO, et al. Alzheimer, sintomas e grupos: uma revisão integrativa. Revista do NESME, 2017; 14(2): 1-27.
CHU LW. Alzheimer’s disease: early diagnosis and treatment. Xianggang yi xue za zhi [Hong Kong Medical Journal], 2012; 18(3): 228-237.
CONGDON EE e SIGURDSSON EM. Tau-targeting therapies for Alzheimer disease. Nature Reviews Neurology, 2018; 1: 1-37.
CRANE PK, et al. Glucose levels and risk of dementia. The New England Journal of Medicine, 2013; 369: 540-548.
DE OLIVEIRA GJM, et al. Fisiopatologia e desenvolvimento do diabetes mellitus tipo 3 e sua relação com a doença de Alzheimer. BRASPEN Journal, 2021; 4(35): 421-426.
GOMES MS. A importância da atividade física na prevenção de doenças crônicas não transmissíveis. Studies in Health Sciences, 2023; 1(3): 45-60.
HAMZÉ R, et al. Type 2 diabetes mellitus and Alzheimer’s disease: Shared molecular mechanisms and potential common therapeutic targets. International journal of molecular sciences, 2022; 23(23): 15287.
KELLAR D e CRAFT S. Brain insulin resistance in Alzheimer’s disease and related disorders: mechanisms and therapeutic approaches. The Lancet Neurology, 2020; 19: 758-766.
KULLENBERG H, et al. Correlations between insulin-degrading enzyme and metabolic markers in patients diagnosed with type 2 diabetes, Alzheimer’s disease, and healthy controls: a comparative study. Endocrine, 2024; 84(2): 450–458.
MATIOLI MNPS e NITRINI R. Mechanisms linking brain insulin resistance to Alzheimer’s disease. Dementia & neuropsychologia, 2015; 9(2): 96–102.
MENEZES LMS, et al. Relação entre doença de Alzheimer e diabetes mellitus tipo 2. Brazilian Journal of Health Review, 2020; 3(6): 16326-16334.
MICHAILIDIS M, et al. Alzheimer’s disease as type 3 diabetes: Common pathophysiological mechanisms between Alzheimer’s disease and type 2 diabetes. International Journal of Molecular Sciences, 2022; 23: 2687.
OTT A, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 1999; 53: 1937-1942.
PENG Y, et al. True or false? Alzheimer’s disease is type 3 diabetes: Evidences from bench to bedside. Ageing research reviews, 2024; 99(102383): 102383.
RHEA EM, et al. State of the science on brain insulin resistance and cognitive decline due to Alzheimer’s disease. Aging and Disease, 2024; 15: 1688-1725.
SEDZIKOWSKA A e SZABLEWSKI L. Insulin and insulin resistance in Alzheimer’s disease. International Journal of Molecular Sciences, 2021; 1: 1-23.
SILVA MVF, et al. Alzheimer’s disease: risk factors and potentially protective measures. Journal of Biomedical Science, 2019; 26(1): 33.
TONG B, et al. Targeting dysregulated lipid metabolism for the treatment of Alzheimer’s disease and Parkinson’s disease: Current advancements and future prospects. Neurobiology of Disease, 2024; 196: 106505.
WELLER J e BUDSON A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Research, 2018; 1: 1-9.
WILLETTE AA, et al. Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurology, 2015; 72(9): 1013.